Axogen deepens nerve repair portfolio through $200m BioCircuit takeover

Through its BioCircuit buyout, Axogen hopes to extend sutureless peripheral nerve repair device, NerveTape's market uptake. Through its BioCircuit buyout, Axogen hopes to extend the market uptake of the former’s NerveTape, a sutureless peripheral nerve repair device. Axogen’s acquisition of BioCircuit adds NerveTape, a sutureless peripheral nerve repair device, to its commercial portfolio. Credit: ijoooo / Shutterstock.com. Florida-based medtech company, Axogen has agreed to acquire BioCircuit Technologies for $200m, further bolstering its presence in the surgical peripheral nerve repair segment. Through the all-cash deal, which Axogen expects to close in Q4 2026, the medtech company will take BioCircuit’s NerveTape under…

Source: Medical Device Network